Tags: Endocrinology by Molecular and Cellular Endocrinology / Terkko Comments Off
Tags: Endocrinology by Diabetes & Metabolism / Terkko Comments Off
WASHINGTON (MedPage Today) — The FDA today approved saxagliptin (Onglyza) for type 2 diabetes treatment, making it the first gliptin-class competitor for sitagliptin (Januvia).
Tags: Endocrinology by MedPage Today Endocrinology Comments Off
Tags: Endocrinology by General and Comparative Endocrinology / Terkko Comments Off
Tags: Endocrinology by Hormones and Behavior / Terkko Comments Off
Tags: Endocrinology by Trends in Endocrinology & Metabolism / Terkko Comments Off